Facial and Oral Cross-Contamination of a 3-Year-Old Child With High Concentration Capsaicin: A Case Report.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
High-concentration topical capsaicin is used to treat different neuropathic pain states. We present a case in which a 3-year-old child orally ingested capsaicin after touching her mother's arm that had been treated with a high-concentration capsaicin patch 3 hours earlier. The child suffered extreme pain and swelling of the lips and tongue. After the use of cleansing gel, external cooling, and drinking milk, the pain lessened over half an hour and subsided after 2 hours. This report aims to raise awareness for this formerly unreported mode of oral contamination.
Identifiants
pubmed: 32633926
doi: 10.1213/XAA.0000000000001258
pii: 02054229-202007000-00005
doi:
Substances chimiques
Capsaicin
S07O44R1ZM
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01258Références
Qutenza Prescribing Information. Available at: https://www.qutenza.com/pdfs/Qutenza_Prescribing_Information.pdf. Updated October 2018. Accessed March 24, 2020.
Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 1:CD007393
Cruccu G, Nurmikko TJ, Ernault E, Riaz FK, McBride WT, Haanpää M. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur J Pain. 2018; 22:700–706
Yong YL, Tan LT, Ming LC, et al. The effectiveness and safety of topical capsaicin in postherpetic neuralgia: a systematic review and meta-analysis. Front Pharmacol. 2016; 7:538
Gaul C, Resch S. Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: a case series. Cephalalgia. 2015; 35:545–550
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Updated November 27, 2017. Accessed March 26, 2020.
Harden RN, Oaklander AL, Burton AW, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines Pain Med. 2013; 14:180–229
Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg. 1998; 86:579–583
Perez RS, Zollinger PE, Dijkstra PU, et al.; CRPS I task force. Evidence based guidelines for complex regional pain syndrome type 1. BMC Neurol. 2010; 10:20
Haar RJ, Iacopino V, Ranadive N, Weiser SD, Dandu M. Health impacts of chemical irritants used for crowd control: a systematic review of the injuries and deaths caused by tear gas and pepper spray. BMC Public Health. 2017; 17:831
Naganawa T, Baad-Hansen L, Ando T, Svensson P. Influence of topical application of capsaicin, menthol and local anesthetics on intraoral somatosensory sensitivity in healthy subjects: temporal and spatial aspects. Exp Brain Res. 2015; 233:1189–1199
Nolden AA, Lenart G, Hayes JE. Putting out the fire - efficacy of common beverages in reducing oral burn from capsaicin. Physiol Behav. 2019; 208:112557